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Since beta-2 microglobulin (B2M) is a surrogate marker for
middle molecular weight uremic toxins and the major protein
component in dialysis-related amyloidosis, it has been
frequently studied in dialysis patients. It is not known,
however, whether B2M has an impact in patients with
chronic kidney disease (CKD) not yet on dialysis. Here we
studied the relationship of plasma B2M levels to clinical and
cardiovascular outcomes in 142 patients (mean age of 67
years) at different stages of CKD. B2M levels increased with
CKD stage and thus were highest in hemodialysis patients.
Baseline B2M levels were associated with vascular
calcification but not with arterial stiffness or bone density.
During a mean follow-up of 969 days, 44 patients died and 49
suffered a cardiovascular event. Higher B2M levels were
independently associated with overall and cardiovascular
mortality and cardiovascular events in the whole cohort and
with cardiovascular events in the predialysis cohort.
Moreover, B2M appeared to be a better predictor than well-
established factors associated with outcomes in this
population, such as estimated glomerular filtration rate
((eGFR), only for predialysis patients), inflammation
biomarkers, and other factors included in a propensity score.
Thus, we confirm the strong relationship between B2M levels
and eGFR and confirm the power of B2M to predict overall
and cardiovascular mortality and cardiovascular events in
patients at different stages of CKD.
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Beta-2 microglobulin (B2M) is a polypeptide with a
molecular weight of 11,800Da. It is present on the surface
of nucleated human cells and thrombocytes and forms part
of the major histocompatibility class I family.1,2 Under
physiological conditions, B2M is generated at a constant rate
and is eliminated by kidneys. Elevated B2M levels are
observed in a range of hematological, immunodeficiency,
autoimmune, and renal diseases.3–6
B2M levels are elevated in patients with kidney failure,
especially in dialysis patients, in whom glomerular filtration is
almost completely absent. Furthermore, it is known that an
elevated concentration of circulating B2M is a potential risk
factor for the development of dialysis-related amyloidosis.7
Indeed, longstanding, the marked elevation of serum B2M is a
prerequisite for the formation of B2M amyloid fibrils, which
are associated with chronic arthropathy and spondylarthro-
pathy after several years of renal replacement therapy.6,7
In addition, B2M is known to be a surrogate marker for the
concentration and removal of other middle-molecular-weight
uremic toxins in dialysis patients. In the HEMO study on 1704
hemodialysis patients, Cheung et al. reported that predialysis
serum B2M predicted mortality, with an 11% increase in
mortality for each 10mg/l increase in B2M level—even after
adjustment for years on dialysis and residual kidney function.8
Hence, the amelioration of B2M clearance during dialysis
might be an important factor for improving outcomes.8,9
It is still unknown whether B2M is only a uremic toxin
marker or also an active player in vascular damage, which is
one of the main mortality factors in chronic kidney disease
(CKD).10 There is preclinical and clinical evidence in favor of
an active role. B2M stimulates osteoclastogenesis, probably
via upregulation of tumor necrosis factor a and interleukin-1
expression.11 An interesting proteomic profiling study in
patients with peripheral arterial disease (PAD)12 identified
B2M as a potential biomarker of PAD. In patients with
PAD, elevated B2M levels correlated with severity of
the disease, independently of other risk factors. It has been
suggested that B2M may damage vessels by participating in
amyloid formation in the vessel wall.12 More recently, B2M
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was found to be independently and significantly associated
with adverse cardiovascular outcomes in patients with
prevalent, asymptomatic carotid atherosclerosis.13
Given that uremic patients are known to be at a high risk
for developing cardiovascular disease and atherosclerosis, we
decided to study the potential impact of B2M on cardiovas-
cular outcomes in CKD patients in general. Indeed, it
remains unknown whether B2M has an impact on CKD
patients who are not yet on dialysis. Hence, we studied B2M
levels in a cohort of patients at different CKD stages, with
special focus on the protein’s relationships with surrogate
markers of bone and vascular disease (including bone
density, arterial stiffness, and vascular calcification) and hard
clinical outcomes (such as cardiovascular events, cardiovas-
cular mortality, and all-cause mortality).
RESULTS
Figure 1 illustrates the distribution of B2M levels. The B2M
level increased with CKD stages. In comparison with a
control group, the increase became statistically significant
from CKD stage 4 onward. When considering nondialyzed
patients only (n¼ 96), there was a significant, inverse
association between B2M levels and estimated glomerular
filtration rate (eGFR), as shown in Figure 2.
Tables 1 and 2 show the main characteristics of the 142
patients as a function of median plasma B2M level. Patients
with B2M levels 48.34mg/l were more likely to be at a
later CKD stage and to have a higher aortic calcification
score, higher circulating phosphate, parathyroid hormone
(PTH), and C-reactive protein (CRP) levels, and lower
hemoglobin and albumin levels. Univariate correlations
between plasma B2M levels and the clinical and biochemical
characteristics of the study population are shown in Table 3.
There was an inverse correlation of B2M with albumin and
hemoglobin but a positive correlation with CRP, phosphate,
and PTH.
In terms of vascular measurements, there was a positive,
linear association between B2M and aortic calcification
score (r2¼ 0.04, P¼ 0.016). No association was found
between B2M and pulse wave velocity (PWV) or bone
mineral density.
During the follow-up period (mean, 969±374 days;
median, 1058; range, 10–1396), 44 patients died (20
predialysis patients and 24 hemodialysis patients) and 49
presented a cardiovascular event (31 predialysis patients and
18 hemodialysis patients). In the cohort as a whole, a B2M
level of48.34mg/l was a significant predictor of overall and
cardiovascular mortality and cardiovascular events
(Po0.0001, Po0.0001, and P¼ 0.005, respectively). Table 4
shows the results of Cox regression analyses for the entire
population. The plasma B2M level was still a predictor of
overall and cardiovascular mortality and cardiovascular
events after adjustment for multiple confounders (age, CRP,
albumin, and hemoglobin) (P¼ 0.001, P¼ 0.038, and
P¼ 0.049, respectively).
In the subgroup of predialysis patients, B2M levels were
not associated with overall (P¼ 0.27) or cardiovascular
mortality (P¼ 0.065); however, a B2M level 46.07mg/l
(the median for predialysis patients) was a significant
predictor of cardiovascular events (P¼ 0.009) in univariate
analysis. The plasma B2M level was still a predictor of
cardiovascular events after adjustment for age, CRP, hemo-
globin, albumin, and eGFR (Table 5).
More importantly, additional Cox models demonstrated
that the B2M level was a better predictor of overall and
cardiovascular mortality, but not of cardiovascular events,
compared with a propensity score that includes CRP,
albumin, hemoglobin, phosphate, and aortic calcification in
the whole group (Table 4). When considering the predialysis
patient group alone, B2M levels were a better predictor of
cardiovascular events compared with age, CRP, albumin,
hemoglobin, phosphate levels, aortic calcification score, and
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Figure 1 |Plasma beta-2 microglobulin levels as a function of
chronic kidney disease (CKD) stage. *Po0.0001 vs. control
group; **Po0.0001 vs. CKD stages 2 and 3; and ***Po0.0001 vs.
CKD stages 4 and 5.
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Figure 2 | Exponential relationship between plasma beta-2
microglobulin level and estimated glomerular filtration rate,
predialysis chronic kidney disease stages 2–5 (n¼ 96,
r2¼ 0.789, Po0.0001).
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eGFR, which were regrouped in a propensity score variable
(Figure 3 and Table 5).
DISCUSSION
Our study confirms that plasma B2M levels are elevated in
CKD patients and that these levels progressively increase with
decreasing GFR and peak in hemodialysis patients. More
interestingly, B2M levels were independently associated with
overall and cardiovascular mortality and cardiovascular
events in the entire cohort and with cardiovascular events
in predialysis patients. Moreover, we show that circulating
B2M is a better predictor of overall and cardiovascular
mortality for the whole cohort and of cardiovascular events
for predialysis patients, compared with well-established
factors associated with outcomes in this population, includ-
ing eGFR, inflammation biomarkers, and others factors
included in a propensity score.
It is well known that the normal serum B2M concentration is
1.5–3mg/l. B2M is usually eliminated by the kidney via glome-
rular filtration and subsequent tubular catabolism.6 Hence, one
can expect (i) circulating B2M levels to be highly correlated with
GFR and (ii) B2M to accumulate in chronic dialysis patients, in
whom GFR is either very low or entirely absent.
Interestingly, we found an association between plasma
B2M levels and overall and cardiovascular mortality and
cardiovascular outcomes in our patient cohort with different
stages of CKD (including predialysis patients). Several studies
Table 1 | Clinical and demographic characteristics of the study
population
Beta-2 microglobulin
All (n=142)
p8.34mg/l
(n=71)
48.34mg/l
(n=71) P
Age, years 67±12 66±12 68±12 0.466
Male gender, n (%) 86 (60) 47 (66) 39 (55) 0.170
Body mass index
(kg/m2)
28±6 29±6 27±6 0.080
Diabetes mellitus, n (%) 60 (42) 30 (50) 30 (50) 0.999
Smoking habit, n (%) 56 (41) 31 (45) 25 (36) 0.298
Presence of CVD, n (%) 43 (31) 22 (31) 23 (32) 0.860
Systolic arterial
pressure, mmHg
153±26 150±23 156±29 0.180
Diastolic arterial
pressure, mmHg
81±12 82±10 81±13 0.578
Pulse pressure, mmHg 72±23 69±22 75±24 0.070
CKD stage, n (%) o0.0001
2 12 (8) 12 (17) 0 (0)
3 37 (26) 36 (51) 1 (1)
4 37 (26) 20 (28) 17 (24)
5 10 (7.5) 0 (0) 10 (15)
5D 46 (32) 3 (4) 43 (60)
Aortic calcification
score on CT, %
(median)
3.04±3.0 (1.9) 2.4±2.6 (1.4) 3.6±3.3 (2.6) 0.036
Aortic calcification
score on X-ray, scale
0–24 (median)
6.3±6.6 (4.5) 4.5±5.3 (26) 7.8±7.2 (6) 0.008
PWV, m/s 14.8±3.8 14.24±3.7 14.9±4 0.273
Bone mineral
density, HU
130.4±48.2 129.7±49.9 130.9±46.9 0.881
Abbreviations: CKD, chronic kidney disease; CT, computed tomography; CVD,
cardiovascular disease; HU: Hounsfield units; PWV, pulse wave velocity.
Data are expressed as the mean±s.d. or, for binary variables, the number (frequency).
Table 2 | Biochemical characteristics of the study population
Beta-2 microglobulin
All (n=142) p8.34mg/l (n=71) 48.34mg/l (n=71) P
Calcium, mmol/l 2.30±0.18 2.32±0.14 2.26±0.21 0.062
Phosphate, mmol/l 1.30±0.46 1.14±0.3 1.43±0.5 o0.0001
Intact PTH, pg/ml 137±138 (85) 89±75 (63) 184±165 (128) o0.0001
Albumin, g/l 38±6 39.9±6 34.9±6 o0.0001
C-reactive protein, mg/l 10.7±23 (3.5) 6.2±13.4 (2.2) 16.2±30.3 (4.1) 0.002
Hemoglobin, g/dl 12±1.7 12.7±1.6 11.4±1.6 o0.0001
GFR-epia, ml/min per 1.73m2 35±19 42.5±17.4 17.1±6.2 o0.0001
Total cholesterol, mmol/l 4.9±1.2 4.9±1.1 4.8±1.3 0.535
LDL cholesterol, mmol/l 2.7±0.9 2.7±0.8 2.5±0.9 0.225
Triglycerides, mmol/l 2.0±1.3 1.8±1.02 2.2±1.5 0.071
Beta-2 microglobulin, mg/l 13.5±12.5 (8.3) 4.7±1.9 (4.7) 22.4±12.3 (19.6) o0.0001
Abbreviations: GFR, glomerular filtration rate; LDL, low-density lipoprotein; PTH, parathyroid hormone.
Data are expressed as the mean±s.d. and, for variables with a non-Gaussian distribution, median.
aCalculated for patients at CKD stages 2–5 (n=96).
Table 3 | Correlations between serum beta-2 microglobulin
levels and selected clinical or biochemical characteristics
Beta-2 microglobulin
r P
Age 0.037 0.661
Systolic arterial pressure 0.075 0.378
Body mass index 0.123 0.145
Albumin 0.437 o0.0001
C-reactive protein 0.292 o0.0001
LDL cholesterol 0.137 0.114
Triglycerides 0.228 0.008
Hemoglobin 0.387 o0.0001
Calcium 0.181 0.032
Phosphate 0.347 o0.0001
Intact PTH 0.459 o0.0001
PWV 0.066 0.436
Aortic calcification score 0.210 0.016
Bone mineral density 0.017 0.846
Abbreviations: LDL, low density lipoprotein; PTH, parathyroid hormone; PWV, pulse
wave velocity; r: Spearman’s correlation coefficient.
For units, please refer to Table 2.
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have demonstrated that serum B2M is an independent,
significant predictor of mortality in dialysis patients.8,14
However, data on predialysis CKD patients are scarce.
In line with our results, Amighi et al.13 recently showed a
strong link between serum B2M levels and cardiovascular
outcomes in a patient population with comorbidity severity
similar to that in CKD patients. The authors studied 1005
patients with prevalent asymptomatic carotid atherosclerosis
and found that B2M was independently and significantly
associated with major adverse cardiovascular events, even
after adjustment for eGFR and CRP. They suggested that
B2M is a novel risk marker for adverse cardiovascular
outcomes in patients with carotid atherosclerosis.
Furthermore, Shinkai et al.15 identified serum B2M as an
independent predictor of all-cause mortality in a population-
based sample of older adults.15 They suggested that the
predictive value of circulating B2M concentration is superior
to that provided by established prognostic factors for
mortality, such as eGFR, cystatin C, and CRP (threshold
for B2M, 1.9mg/l).
Table 4 | For the entire cohort, univariate and multivariate
Cox regression analyses of risk factors at baseline for all-
cause mortality, cardiovascular mortality and cardiovascular
event-free survival with the plasma B2M level entered as
either a categorical variablea (B2M48.34 vs. B2Mp8.34mg/l)
or a continuous variableb
HR 95% CI P
Overall mortality (events n=44)
Unadjusted
B2Ma 3.87 1.95–7.67 o0.0001
Ln B2Mb 1.94 1.39–2.71 o0.0001
Model 1 including Ln B2M, age,
Ln CRP, Hb, and albuminc
Ln B2Mb 1.90 1.30–2.78 0.001
Age 1.05 1.02–1.08 0.002
Model 2 including B2M, age, and
propensity scored
B2Ma 4.11 2.00–8.43 0.0001
Age 1.05 1.02–1.09 0.001
Cardiovascular mortality (events n=24)
Unadjusted
B2Ma 4.81 1.79–12.91 o0.0001
Ln B2Mb 1.76 1.12–2.76 0.013
Model 1 including Ln B2M, age,
Ln CRP, Hb, and albuminc
Ln B2Mb 1.71 1.63–2.83 0.038
Age 1.04 0.99–1.075 0.056
Model 2 including B2M, age and
propensity scored
B2Ma 4.75 1.76–12.83 0.002
Age 1.05 1.007–1.091 0.02
Cardiovascular event-free survival (events n=49)
Unadjusted
B2Ma 2.33 1.29–4.16 0.005
Ln B2Mb 1.51 1.11–2.05 0.009
Model 1 including Ln B2M, age,
Ln CRP, Hb and albuminc
Ln B2Mb 1.32 1.08–2.80 0.048
Age 1.03 1.01–1.06 0.017
Model 2 including B2M, age and
propensity scoree
Age 1.03 1.004–1.06 0.026
Propensity score 7.30 2.29–23.23 0.0008
Abbreviations: B2M, beta-2 microglobulin; CI, confidence interval; CRP, C-reactive
protein; Hb, hemoglobin; HR, hazard ratio.
P-values are stated for the trend across categories.
aPlasma B2M level entered as a categorical variable (B2M48.34 vs. B2Mp8.34mg/l).
bPlasma B2M level entered as continuous variable.
cLn CRP, hemoglobin, and albumin were not selected in the models.
dPropensity score (included albumin, CRP, hemoglobin and phosphate levels, and
aortic calcification score) was not selected in the model.
eB2M was not selected in the model.
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Figure 3 |Kaplan–Meier estimates of the probability of
cardiovascular event-free survival for the subgroup of
predialysis patients, as a function of median plasma beta-2
microglobulin concentration. Results were adjusted for
propensity score, which included age, albumin, C-reactive protein,
hemoglobin, and phosphate levels, aortic calcification score, and
estimated glomerular filtration rate.
Table 5 | For predialysis patients: univariate and multivariate
Cox regression analyses of risk factors at baseline for
cardiovascular event-free survival, with the plasma B2M
entered as either a categorical variablea (B2M46.07 vs.
B2Mp6.07mg/l) or a continuous variableb
Models of patient survival
(event n=31) HR 95% CI P
Unadjusted
B2Ma 2.64 1.24–5.64 0.009
Ln B2Mb 2.01 1.09–3.69 0.024
Model 1 including B2M, age, Ln
CRP, Hb, albumin, and eGFRc
Ln B2Mb 1.83 1.32–3.05 0.007
Age 1.04 1.01–1.08 0.008
Model 2 including B2M, and
propensity scored
B2Ma 3.13 1.37–7.18 0.007
Abbreviations: B2M, beta-2 microglobulin; CI, confidence interval; HR, hazard ratio.
aPlasma B2M level entered as a categorical variable (B2M46.07 vs. B2Mp6.07mg/l).
bPlasma B2M level entered as continuous variable.
cIn model 1 and 2: Ln CRP, hemoglobin, albumin, and eGFR were not selected in the
models.
dIn model 2: Propensity score (including age, albumin, CRP, hemoglobin, phosphate,
aortic calcification score, and eGRF) was not selected in the model.
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Interestingly, systematic proteomic profiling-based screen-
ing for PAD biomarkers led to the identification of B2M as
the most relevant candidate. The authors suggested that B2M
might damage vessels by participating in amyloid formation
in the vascular wall.12
In view of these data as a whole, the possibility that high
levels of circulating B2M have a direct pathophysiological
role in vascular disease deserves serious consideration. The
association between B2M levels and aortic calcification found
in our cohort suggests that this solute may also have a role in
the development of uremia-related cardiovascular disorders.
The involvement of B2M in the inflammatory process, as
highlighted in previous reports, could explain the observed
association between vascular calcification and circulating
levels of this uremic toxin.11
Several reports have suggested that the uremic milieu has a
harmful influence on the vascular system. In an in vitro
study, high serum levels of B2M and indole-3-acetic acid
were associated with low counts of circulating CD34þ
CD133þ endothelial progenitor cells;16 the latter
contribute to vessel repair and neovascularization and show
a decrease in their migration ability in the presence of uremic
serum.17 The uremic milieu may disturb vascular repair
mechanisms in patients with kidney failure.18 Moreover, it
has been demonstrated that other uremic toxins (such as
indoxyl sulfate, p-cresyl sulfate, and guanidine compounds)
inhibit endothelial proliferation and wound repair.19–21
Our present data suggest that B2M should be added to the
list of suspects. However, we did not find a correlation
between B2M levels and arterial stiffness. Previous studies
have found such an association in non-CKD patients.22,23
This discrepancy may be due to the different types of
recruitment and techniques used for arterial stiffness
measurement. One study recorded brachial PWV, which is
not a ‘gold standard’ parameter, whereas we used carotid-
femoral PWV. Moreover, the low degree of PWV variability
in our cohort might have precluded the identification of such
an association.
A variety of reports have suggested that B2M may be
involved in metabolic bone disease in CKD. B2M appears to
upregulate TNFa and IL-1 expression in a concentration-
dependent manner. A TNFa-neutralizing antibody blocked
B2M-induced osteoclast formation, suggesting that B2M
stimulates osteoclastogenesis and has a direct role in bone
destruction in CKD patients.11 In addition, serum B2M has
been suggested to be a marker of bone remodeling in
postmenopausal women.24,25
Despite this evidence of B2M’s putative involvement in
bone metabolism, we failed to find a relationship between
B2M levels and bone density in our study population. The
lack of a relationship may be related to the bone mass
measurement sites studied here and/or to the fact that
computed tomography (CT) is not an ideal method for
evaluating bone density—especially in the absence of a
phantom comparator, and certainly does not allow assess-
ment of bone turnover.
Limitations of the present study include the single-center
design and the relatively small size of our cohort. However,
the use of propensity scoring included in a Cox model with a
backward selection procedure allowed us to adjust for
multiple confounding factors and to demonstrate a better
prediction of plasma B2M compared with several well-known
factors associated with outcomes in this population, includ-
ing eGFR, biomarkers of inflammation, and other factors
included in the propensity score. The major strength of
our study relates to the enrolment of patients at different
stages of CKD.
In conclusion, we measured B2M levels in patients at
various CKD stages and confirmed a strong relationship
between B2M and eGFR. More importantly, we highlighted
the discriminant power of B2M as a predictor of overall and
cardiovascular mortality and cardiovascular events in
patients at different stages of CKD. These findings are
compatible with the view that B2M has a direct role in the
development of uremia-related cardiovascular disorders.
MATERIALS AND METHODS
Patient selection
Over an 18-month period (from January 2006 to June 2007), a total
of 150 Caucasian, prevalent CKD patients were recruited from the
Nephrology Department’s outpatient clinic at Amiens University
Hospital. All patients gave their informed, written consent. The
study was approved by the local Investigational Review Board and
conducted in accordance with the ethical principles of the
Declaration of Helsinki.
Patients included in the study were over the age of 40, with a
confirmed diagnosis of CKD (defined as being on hemodialysis or
having two previous, estimated creatinine clearances, calculated
according to Cockcroft and Gault formula, with an interval of 3–6
months and values o90ml/min per 1.73m2). Stage 5D CKD
patients were receiving long-term hemodialysis treatment three
times a week for at least 3 months. Exclusion criteria consisted of the
presence of chronic inflammatory disease, atrial fibrillation,
complete heart block, abdominal aorta aneurysm, the presence of
aortic and/or femoral artery prosthesis, primary hyperparathyroid-
ism, kidney transplantation, and any acute cardiovascular event in
the 3 months before screening for inclusion. The 142 patients who
met all inclusion criteria and had available plasma B2M assay results
were included in the present analysis.
Study protocol
All patients were hospitalized for the day in order to perform
laboratory blood tests, blood pressure measurements, PWV
determination, lateral lumbar X-ray, and multislice spiral CT
scanning. For a given patient, all examinations were conducted
between 0900 and 1400 hours on the same day. Hemodialysis
patients were examined on a dialysis-free day or, if this was not
possible, the morning before a dialysis session. These patients
underwent 4-h standard hemodialysis sessions three times a week.
The mean time since initiation of dialysis was 29±36 months
(median, 12 months). Of these patients, 78% were being treated
with erythropoietin-stimulating agents, 72% had vitamin D
supplementation, and 50% were being treated with sevelamer. Each
patient was interviewed, with particular focus on comorbidities and
disease history (especially any previous vascular events). The
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patients’ medical files were reviewed in order to identify and record
any concomitant medications. For descriptive purposes, patients who
reported current or past use of insulin and/or oral hypoglycemic
drugs were considered to have diabetes. Previous cardiovascular
disease was defined as a history of any of the following events:
myocardial infarction, stroke, heart failure, angina pectoris, or
surgical procedures for angina or coronary/peripheral artery disease
(including percutaneous transluminal angioplasty).
Laboratory tests
Blood samples were collected in the morning, before the other
investigations were conducted. Selected assays were performed after
the samples had been frozen and stored at 80 1C. Serum calcium,
phosphate, albumin, cholesterol, hemoglobin, creatinine, and CRP
levels were assayed in an on-site biochemistry laboratory using
standard autoanalyzer techniques (the Modular IIP system, Roche
Diagnostics, Basel, Switzerland). Serum-intact PTH (iPTH 1–84)
was determined with a chemiluminometric immunoassay (Liaison
N-tact PTH CLIA, Diasorin, Stillwater, MN). The plasma concen-
tration of B2M was measured by immunonephelometry (BNProS-
pec, Siemens Healthcare (Dade Behring), Marburg, Germany).
Reference values for B2M were obtained from 27 healthy subjects
(control group) in the same laboratory, with a mean value of
1.25±0.19mg/l. Serum cystatin C levels were determined by
immunonephelometry (N Latex Cystatin C, Dade Behring). In
order to describe the true GFR as closely as possible, the estimated
GFR combining creatinine and cystatin C measurements (CKD-epi)
was calculated for all nondialyzed patients according to the
following, recently published ‘CKD-epi’ equation:26 177.6
creatinine0.65 cystatin C0.57 age0.20 (0.82 if female). For
descriptive purposes, patients were classified into CKD stages,
according to the National Kidney Foundation’s Kidney Disease
Outcomes Quality Initiative guidelines.27
PWV evaluation
Carotid-femoral PWV was determined automatically with a
dedicated, validated device (Complior Colson, Createch Industrie,
Massy, France), as previously described.28 The PWV was evaluated
with two pressure probes by a trained physician. Simultaneously
recorded pulse waveforms were obtained transcutaneously over the
common carotid artery and the femoral artery in the groin. PWV
was calculated as the distance between recording sites measured over
the body’s surface (L), divided by the time interval (t) between the
feet of the flow waves (PWV¼ L/t); this result was averaged over 10
cardiac cycles.29 This automatic method has been validated
previously and has an intraobserver repeatability coefficient of
0.93 and an interobserver reproducibility coefficient of 0.89.28,29
Abdominal aorta imaging with plain radiography
A technique similar to that described by Kauppila et al.30 was used
to obtain images of the lower abdominal aorta and generate an
aortic calcification score. All X-rays were reviewed by two
independent investigators and a consensus on the interpretation
was reached in all cases.
Multislice spiral CT
To quantify the presence and extent of aortic calcifications, each
patient underwent a multislice spiral CT scan. All examinations were
performed with a 64-detector CT scanner (Lightspeed VCT, GE
Healthcare, Milwaukee, WI).
The volume acquisition started at the aortic hiatus of the
diaphragm and ended at the third lumbar vertebra. The scanning
parameters were as follows: collimation 64 0.625mm2; slice
thickness 0.625mm; pitch 1; gantry rotation speed 0.5 s per rotation;
tube voltage 120 kV; and tube current 300mA.
The volume acquisition was analyzed with commercially
available software (Volume Viewer, GE Healthcare). The abdominal
aorta was segmented manually. To reduce errors due to noise, a
threshold of 160UH was applied. The total calcification volume was
calculated as the sum of all voxels in the remaining volume. The
abdominal aorta calcification score was calculated as follows: ((total
calcification volume)/(aorta wall surface area)*100)).
To determine bone density, a measurement halfway through the
twelfth thoracic vertebra was performed. The CT image analysis was
based on conversion of the bone tissue attenuation (measured in
Hounsfield units) into grams of hydroxyapatite per cubic centimeter
of bone.31 In the absence of a mineral reference phantom in the
present study, we measured bone attenuation—the best surrogate
marker of density we could provide and the core measurement that
all CT programs use to determine bone mineral density. An
experienced radiologist from Amiens University Medical Center
assessed trabecular bone attenuation.
Survival
Death records were established prospectively, by considering all
patients included at least 20 months before the end of the study date
(1 January 2010). Each medical chart was reviewed and the cause of
death was assigned by a physician on the basis of all the available
clinical information. For out-of-hospital deaths, the patient’s family
doctor was interviewed to obtain pertinent information on the
cause. Cardiovascular mortality was defined as any death directly
related to cardiovascular system dysfunction (stroke, myocardial
infarction, congestive heart failure, or sudden death). Cardiovas-
cular events were defined as cardiovascular death or any adverse
event directly related to a cardiovascular system dysfunction (stroke,
angina pectoris/myocardial infarction, congestive cardiac failure,
peripheral ischemia, or new-onset arrhythmia) or surgical proce-
dures for angina or coronary/peripheral arterial disease.
Statistical analyses
Data are expressed as mean±s.d., median, and range or frequency,
as appropriate. In the study population, patients were stratified
according to the median serum B2M level (i.e. serum B2Mp8.34 vs.
serum B2M48.34mg/l for the entire cohort, or according to the
median value of 6.07mg/l for predialysis patients) for descriptive
and analytical purposes. This median value appears to be a good
cutoff according to the ROC curve for mortality, with a sensitivity of
0.75 and a specificity of 0.61.
Intergroup comparisons were made using a w2 test for categorical
variables and Student’s t-test or a Mann–Whiney test for continuous
variables. Because of non-Gaussian distribution of B2M, Spearman’s
rank correlations were used to assess the relationships between
serum B2M levels and selected clinical or biochemical variables.
Adjusted Kaplan–Meier curves were estimated using the Inverse
Probability of Treatment Weighting method,32 and comparison of
survival curves was made with the logrank test using a robust
estimate of variance. Univariate and multivariate analyses using
backward stepwise procedure of mortality were performed using a
Cox proportional hazards model for overall survival and cardiovas-
cular event-free survival as a function of serum B2M levels (either
categorized by the median value or as a continuous variable). As the
1302 Kidney International (2012) 82, 1297–1303
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log linearity criterion for B2M, as a continuous variable, was not
fulfilled (shown by the cumulative sums of Martingale-based
residuals), B2M was log-normalized for use in Cox univariate
models. Hazard ratio was estimated with a 95% confidence interval.
In multivariate analysis, we then adjust for relevant potential
confounders including age, CRP (log-normalized), hemoglobin, and
albumin for the whole cohort (Models 1 in Table 4) and age, CRP
(log-normalized), hemoglobin, albumin, and eGFR for the pre-
dialysis patient subgroup (Model 1 in Table 5).
To confirm whether B2M is a better predictor of outcome
particularly for predialysis patients compared with well-known
factors associated with outcomes in this population, including eGFR,
inflammation biomarkers, and other factors, and in view of the
limited number of events, we performed an additional model using
Cox regression analyses with the backward selection method
including a propensity score; this model took account of each
individual’s probability of having a B2M above or below the median
value of the whole and predialysis population. Propensity score33 was
built using a logistic model including all variables associated with
B2M (as a binary variable) in the univariate logistic model at 20%
alpha level: age, albumin level, CRP level, hemoglobin level,
phosphate level, aortic calcification score, and eGFR for predialysis
patients (Model 2 in Table 5), whereas albumin level, CRP level,
hemoglobin level, phosphate level, and aortic calcification score were
included in the propensity score for the whole cohort (Model 2 in
Table 4). A P-valuep0.10 was considered to be statistically significant
in the univariate Cox model and p0.05 in the multivariate Cox
model. All statistical analyses were performed using SPSS software
(SPSS, Chicago, IL, USA), version 13.0 for Windows (Microsoft
Corp, Redmond, WA, USA) and R 2.12.0 for propensity score and the
Inverse Probability of Treatment Weighting methods.
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